ISN Journal Summaries on Immunosuppression Treatments for Glomerular Disease and Blood Disorders With Kidney Involvement
Kidney International®
This study analyzed 1,912 adults with glomerular disease from Canada to evaluate the cardiovascular risks associated with immune therapies used for treatment.
The findings reveal that prolonged exposure to calcineurin inhibitors and cyclophosphamide is linked to a higher risk of cardiovascular events, such as heart attacks and strokes. Corticosteroids and antimetabolites were not associated with an increased risk.
These results suggest that different therapies for glomerular disease carry varying cardiovascular risk profiles, which could guide treatment discussions if validated in other patient groups.
Kidney International Reports®
Clinical Spectrum and Outcome of Kidney Involvement in Non-Langerhans Histiocytosis
This study evaluated kidney involvement in Rosai-Dorfman disease (RDD) and Erdheim-Chester disease (ECD) through a retrospective analysis of 48 patients. RDD was characterized by renal masses without kidney symptoms, while ECD commonly presented with perirenal soft tissue involvement and occasional kidney-related symptoms.
Treatments included steroids and lenalidomide-dexamethasone for RDD and interferon-alpha, BRAF inhibitors, or cytarabine for ECD. Responses to treatment varied, with some patients showing improved kidney function while others experienced irreversible kidney dysfunction. The findings highlight the importance of early diagnosis and timely treatment to preserve kidney function, particularly in ECD.